Cupid Ltd., a prominent manufacturer and supplier of healthcare products, witnessed a significant surge in its stock price today following the announcement of strong September quarter (Q2) expectations and an upward revision of its financial outlook for fiscal year 2027 (FY27).
Robust Financial Projections
The company now projects net sales for the September quarter to exceed Rs 200 crore. For the full FY27, Cupid has raised its revenue guidance to Rs 800 crore and its net profit guidance to Rs 250 crore. This revised outlook reflects sustained momentum across key business verticals and improved visibility in both domestic and international markets.
Key Growth Drivers
Several factors are contributing to Cupid's optimistic forecast. The company highlighted the continued expansion of its domestic Fast-Moving Consumer Goods (FMCG) business, which includes products like fragrances, deodorants, hair removal sprays, and face wash. Progress towards the operationalization of its Palava manufacturing facility is also expected to bolster production capabilities. Furthermore, consistent growth across its healthcare and personal care portfolio underscores the company's strong market position.
Strategic Developments and Market Performance
In strategic moves, Cupid approved the conversion of up to 30 lakh warrants of Baazar Style Retail Limited into equity shares at Rs 328.25 per share. The company also secured in-principle approval for a new manufacturing venture in South Africa. This facility, adopting an asset-light model, aims to support local manufacturing and serve as a platform for expansion across the African continent and other international markets. Additionally, Cupid strengthened its partnership with GII Healthcare Investment Limited through an additional $5 million follow-on investment.
The company's shares rose 0.77 percent to reach a new record high of Rs 314 on the BSE. Over the past six months, the stock has delivered a remarkable 257.60 percent return. During the September quarter, Cupid shares were included in the BSE Group ‘A’, NIFTY Small Cap 250, and the FTSE Emerging Markets All Cap Index, reflecting its growing prominence in the market.